SCB-2019

Last updated

SCB-2019
Vaccine description
Target SARS-CoV-2
Vaccine type Protein subunit
Clinical data
Routes of
administration 		Intramuscular
Identifiers
DrugBank

SCB-2019 is a protein subunit COVID-19 vaccine developed by Clover Biopharmaceuticals using an adjuvant from Dynavax technologies. [1] Positive results of Phase I trials for the vaccine were published in The Lancet [2] and the vaccine completed enrollment of 29,000 participants in Phase II/III trials in July 2021. [3] In September 2021, SCB-2019 announced Phase III results showing 67% efficacy against all cases of COVID-19 and 79% efficacy against all cases of the Delta variant. Additionally, the vaccine was 84% effective against moderate cases and 100% effective against hospitalization. [4]

Contents

SCB-2019 is being funded by CEPI as part of COVAX [5] and has received advanced purchase orders from GAVI for 400 million doses, [6] with production to begin in 2021. [7]

Medical uses

The vaccine was administered in 2 doses in 4 weeks. [8]

Efficacy

In September 2021, SCB-2019 announced Phase III results showing 67.2% efficacy against all cases of COVID-19 of any degree of severity, 83.7% efficacy against moderate-to-severe disease, and 100% against hospitalisation and severe cases. [4] [7] Additionally, the vaccine was 79% effective against all cases of Delta. Of the 207 cases found during the trials, 52 were from the vaccinated group and 155 from the placebo group. [4] These Phase II/III results have been published in the Lancet. [9]

Clover expects to submit its Phase III results for approval by the World Health Organization, European Medicines Agency, and China's NMPA in the fourth quarter of 2021. [7]

Efficacy against variants

In Phase III trials, SCB-2019 showed efficacy of 81.7% for moderate-to-severe cases of COVID-19 caused by Delta, 91.8% for Gamma, and 58.6% for Mu. [4] [7] 56 Delta cases, 37 Mu cases, and 13 Gamma cases were recorded during the trials. [4]

Pharmacology

Subunit vaccines contain parts of the virus selected to stimulate an immune response, without including the entire virus. Because the fragments are incapable of causing disease, subunit vaccines are considered very safe. Subunit vaccines in widespread use include the Hepatitis B vaccine and Pertussis vaccine. [10]

SCB-2019 has a trimeric form of the SARS-CoV-2 spike protein (S-Trimer) combined with one of two different adjuvants AS03 (GlaxoSmithKline) or CpG/Alum (Dynavax). [11] [2] The vaccine displays the spike protein in its natural three-part form, leading to a potentially better immune response. [5] The vaccine is similar to other subunit COVID-19 vaccines including Novavax, Abdala, and ZF2001. [12]

The vaccine is stable for at least six months under normal refrigeration conditions and at least one month at 40 degrees Celsius. [7]

Manufacturing

CEPI and COVAX investment

SCB-2019 is funded by CEPI as part of the COVAX. By November 2020, CEPI had invested $328 million to develop the vaccine. If the vaccine was successful, CEPI's investment would help scale-up production to over 1 billion doses a year. [13] Previously, CEPI provided $3.5 million to support Phase I trials and later an additional $66 million in July 2020 to expand clinical testing and prepare sites for Phase II/III trials. [5]

In February 2021, Clover decided to proceed with the adjuvant from Dynavax for its Phase II/III trials over GlaxoSmithKline after evaluating manufacturing considerations. [14] Separately, CEPI provided $99 million funding to Dynavax to produce its adjuvant for various COVID-19 vaccines. [14]

Vaccine production is expected to begin in 2021. [7]

Orders

In June 2020, GAVI announced an agreement with Clover for the purchase of 64 million doses in 2021 and an additional 350 million doses in 2022. [1] [6]

Clinical trials

Phase I & II trials

In June 2020, Phase I trial were launched to assess safety, reactogenicity, and immunogenicity at multiple dose levels with 151 participants in Perth, Australia using 2 separate adjuvants, AS03 and CpG/Alum. [15] [16] [1] In results published in The Lancet , SCB-2019 resulted in a strong immune responses against COVID-19, with high viral neutralizing activity (antibody geometric mean titres were 1567–4452 with AS03 and 174–2440 with CpG/Alum). Both adjuvanted vaccines were well tolerated and determined to be suitable for further clinical development. [2]

In August 2021, a Phase II trial will launch to assess immunogenicity and safety with 800 participants in China. [17]

Phase II/III trials

In March 2021, a larger combined-Phase II/III trial was launched to evaluate efficacy, immunogenicity, reactogenicity, and safety of the CpG/Alum adjuvated SCB-2019 vaccine. [18] [1] In July 2021, enrollment in the Phase II/III trials was completed with 45% of the 29,000 participants in Asia, 45% in Latin America and the rest in Europe and Africa. [3] [19]

Efficacy against variants

In September 2021, results published in The Journal of Infectious Diseases showed SCB-2019 induced antibodies responses up to 184 days in the Phase I trial. Additionally, the vaccine produced neutralizing antibodies against three of the most common variants of concern; Alpha, Beta, and Gamma. [20]

In September 2021, the COVID-19 vaccine candidate showed 79% efficacy against the delta variant in its Phase II/III trials. [21]

Related Research Articles

A subunit vaccine is a vaccine that contains purified parts of the pathogen that are antigenic, or necessary to elicit a protective immune response. Subunit vaccine can be made from dissembled viral particles in cell culture or recombinant DNA expression, in which case it is a recombinant subunit vaccine.

<span class="mw-page-title-main">Novavax</span> American biotechnology company

Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19.

<span class="mw-page-title-main">Valneva COVID-19 vaccine</span> Vaccine candidate against COVID-19

Valneva COVID-19 vaccine is a COVID-19 vaccine developed by French biotechnology company Valneva SE in collaboration with the American biopharmaceutical company Dynavax Technologies.

<span class="mw-page-title-main">Novavax COVID-19 vaccine</span> Vaccine against COVID-19

The Novavax COVID-19 vaccine, sold under the brand names Nuvaxovid and Covovax, among others, is a subunit COVID-19 vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI).

<span class="mw-page-title-main">ZF2001</span> Vaccine against COVID-19

ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and Uzbekistan.

<span class="mw-page-title-main">CoVLP</span> COVID-19 vaccine candidate produced in a plant

CoVLP was a COVID-19 vaccine developed by Medicago in Canada and GlaxoSmithKline (GSK). The product and Medicago, Inc. were owned by Mitsubishi who terminated the company and program in February 2023 due to high international market competition for COVID-19 vaccines.

<span class="mw-page-title-main">Soberana 02</span> Vaccine against COVID-19

Soberana 02 or Soberana 2, technical name FINLAY-FR-2, is a COVID-19 vaccine produced by the Finlay Institute, a Cuban epidemiological research institute. The vaccine is known as PastoCovac in Iran, where it has been developed in collaboration with the Pasteur Institute of Iran.

<span class="mw-page-title-main">CureVac COVID-19 vaccine</span> Vaccine candidate against COVID-19

The CureVac COVID-19 vaccine was a COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI). The vaccine showed inadequate results in its Phase III trials with only 47% efficacy. In October 2021 CureVac abandoned further development and production plans for CVnCoV and refocused efforts on a cooperation with GlaxoSmithKline.

<span class="mw-page-title-main">Sanofi–GSK COVID-19 vaccine</span> Vaccine candidate against COVID-19

The Sanofi–GSK COVID-19 vaccine sold under the brand name VidPrevtyn Beta, is a COVID-19 vaccine developed by Sanofi Pasteur and GSK.

<span class="mw-page-title-main">Nanocovax</span> Vaccine candidate against COVID-19

Nanocovax is a Vietnamese COVID-19 vaccine candidate developed by Nanogen Pharmaceutical Biotechnology JSC. It is a subunit vaccine.

<span class="mw-page-title-main">MVC COVID-19 vaccine</span> Vaccine against COVID-19

The MVC COVID-19 vaccine, designated MVC-COV1901 and also known as the Medigen COVID-19 vaccine, is a protein subunit COVID-19 vaccine developed by Medigen Vaccine Biologics Corporation in Taiwan, American company Dynavax Technologies, and the U.S. National Institutes of Health.

<span class="mw-page-title-main">Corbevax</span> Vaccine against COVID-19

Corbevax is a protein subunit COVID-19 vaccine developed by Texas Children's Hospital Center for Vaccine Development and Baylor College of Medicine in Houston, Texas and Dynavax technologies based in Emeryville, California. It is licensed to Indian biopharmaceutical firm Biological E. Limited (BioE) for development and production.

<span class="mw-page-title-main">V-01</span> Vaccine candidate against COVID-19

V-01 is a protein subunit COVID-19 vaccine candidate developed by a subsidiary of Livzon Pharmaceutical Group Inc.

<span class="mw-page-title-main">Razi Cov Pars</span> Vaccine candidate against COVID-19

Razi Cov Pars is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute Razi Cov Pars is a covid-19 vaccine based on recombinant protein, which is being produced by Razi Vaccine and Serum Research Institute, Iran. This vaccine is the first injectable-intranasal recombinant protein corona vaccine.It's the second Iranian COVID-19 vaccine reaching human trials and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine.

<span class="mw-page-title-main">COVAX-19</span> Vaccine candidate against COVID-19

COVAX-19 is a recombinant protein-based COVID-19 vaccine developed by South Australian-based biotech company Vaxine, in collaboration with CinnaGen, a private company with operations in the Middle East. It is under clinical trial in collaboration with the Iranian company CinnaGen.

<span class="mw-page-title-main">Skycovione</span> Vaccine candidate against COVID-19

Skycovione is a COVID-19 vaccine candidate developed by SK Bioscience and the Institute for Protein Design of the University of Washington, It is South Korea's first homegrown COVID-19 vaccine and utilizes GSK's AS03 adjuvant technology.

<span class="mw-page-title-main">COVID-19 vaccine clinical research</span> Clinical research to establish the characteristics of COVID-19 vaccines

COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy, effectiveness, and safety. As of November 2022, 40 vaccines are authorized by at least one national regulatory authority for public use:

<span class="mw-page-title-main">Noora (vaccine)</span> Vaccine candidate against COVID-19

Noora is a COVID-19 vaccine candidate developed by Baqiyatallah University of Medical Sciences in collaboration with Plasma Darman Sarv Sepid Co. in Iran. Introduced in June 2021, it was announced as having "successfully passed the first phase of its clinical trial" two months later. The clinical trial reported in the Journal of Medical Virology met a critical scrutiny in May 2023, after which the journal declared it as an invalid study and retracted it in March 2024. Independent research in 2024 indicated that the vaccine is very weak unlikely useful for the later variants of SARS-CoV-2.

<span class="mw-page-title-main">Soberana Plus</span> Vaccine

Soberana Plus, technical name FINLAY-FR-1A, is a COVID-19 candidate vaccine produced by the Finlay Institute, a Cuban epidemiological research institute.

<span class="mw-page-title-main">S-268019</span> Vaccine candidate against COVID-19

S-268019-b is a protein subunit COVID-19 vaccine candidate developed by Shionogi.

References

  1. 1 2 3 4 "Chinese biotech firm Clover signs deal to make millions of vaccines". South China Morning Post. 30 June 2021. Retrieved 8 July 2021.
  2. 1 2 3 Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I, et al. (February 2021). "Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial". Lancet. 397 (10275): 682–694. doi:10.1016/S0140-6736(21)00241-5. PMC   7906655 . PMID   33524311.
  3. 1 2 "Clover Biopharma completes enrollment in SPECTRA phase 2/3 trial of Covid-19 vaccine candidate, SCB-2019". Pharmabiz. Archived from the original on 11 July 2021. Retrieved 8 July 2021.
  4. 1 2 3 4 5 Liu R (22 September 2021). "Clover's vaccine 67% effective against COVID, 79% against Delta variant in large trial". Reuters. Retrieved 22 September 2021.
  5. 1 2 3 Rogers J (July 2021). "From lab to potential jab: Clover's COVID-19 vaccine story". CEPI. Retrieved 8 July 2021.
  6. 1 2 "Gavi signs agreement with Clover Biopharmaceuticals for supply to COVAX". www.gavi.org. Retrieved 8 July 2021.
  7. 1 2 3 4 5 6 "Clover's COVID-19 shot tames delta in pivotal study, delivering boost to global vaccination campaign". FierceBiotech. 22 September 2021. Retrieved 22 September 2021.
  8. ↑ Richmond PC, Hatchuel L, Pacciarini F, Hu B, Smolenov I, Li P, et al. (November 2021). "Persistence of the Immune Responses and Cross-Neutralizing Activity With Variants of Concern Following 2 Doses of Adjuvanted SCB-2019 Coronavirus Disease 2019 Vaccine". The Journal of Infectious Diseases. 224 (10): 1699–1706. doi: 10.1093/infdis/jiab447 . PMC   8499965 . PMID   34480575.
  9. ↑ Bravo L, Smolenov I, Han HH, Li P, Hosain R, Rockhold F, et al. (January 2022). "Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial". Lancet. 399 (10323): 461–472. doi:10.1016/S0140-6736(22)00055-1. PMC   8776284 . PMID   35065705.
  10. ↑ "What are protein subunit vaccines and how could they be used against COVID-19?". www.gavi.org. Retrieved 8 July 2021.
  11. ↑ Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi: 10.1146/annurev-med-042420-113212 . PMID   34637324. S2CID   238747462.
  12. ↑ Zimmer C, Corum J, Wee SL (10 June 2020). "Coronavirus Vaccine Tracker". The New York Times. ISSN   0362-4331 . Retrieved 8 July 2021.
  13. ↑ "CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure". CEPI. 3 November 2020. Retrieved 8 July 2021.
  14. 1 2 Liu R (1 February 2021). "Clover ends COVID-19 vaccine partnership with GSK". Reuters. Retrieved 8 July 2021.
  15. ↑ Clinical trial number NCT04405908 for "SCB-2019 as COVID-19 Vaccine" at ClinicalTrials.gov
  16. ↑ "Clover Biopharmaceuticals starts Phase I Covid-19 vaccine trial". Clinical Trials Arena. 20 June 2020. Archived from the original on 11 October 2020. Retrieved 25 June 2020.
  17. ↑ Clinical trial number NCT04954131 for "Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults in China" at ClinicalTrials.gov
  18. ↑ Clinical trial number NCT04672395 for "A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (SCB-2019)" at ClinicalTrials.gov
  19. ↑ "Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2/3 Clinical Trial for its COVID-19 Vaccine Candidate". cloverbiopharma.com. Clover Biopharmaceuticals. 6 July 2021. Archived from the original on 6 July 2021. Retrieved 13 July 2021.
  20. ↑ Richmond PC, Hatchuel L, Pacciarini F, Hu B, Smolenov I, Li P, et al. (November 2021). "Persistence of the Immune Responses and Cross-Neutralizing Activity With Variants of Concern Following 2 Doses of Adjuvanted SCB-2019 Coronavirus Disease 2019 Vaccine". The Journal of Infectious Diseases. 224 (10): 1699–1706. doi: 10.1093/infdis/jiab447 . PMC   8499965 . PMID   34480575.
  21. ↑ "Clover's COVID-19 shot tames delta in pivotal study, delivering boost to global vaccination campaign". FierceBiotech. 22 September 2021. Retrieved 23 September 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.